225 - Imatinib (IM) discontinuation in chronic myeloid leukemia (CML): A pharmacogenetic score for patients with durable complete molecular response (CMR)
Autor: | Campiotti, L., Ferrari, M., Orlandi, E.M., Suter, M.B., Squizzato, A., Guasti, L., Marino, F., Cosentino, M. |
---|---|
Zdroj: | In European Journal of Cancer December 2016 69 Supplement 1:S76-S76 |
Databáze: | ScienceDirect |
Externí odkaz: |